ATMP

The pricing policy of Hemgenix presents a possible option to overcome high upfront costs for one-time therapies...

Ebvallo is the first authorized allogeneic T-cell immunotherapy...

For Roctavian a periodic outcome-based adjustment of the reimbursement price was agreed on...

For HTA on Upstaza, indirect comparisons were worth the effort ....

RCTs for CAR-T cell therapies are becoming more and more common – an RCT is also conducted for Carvykti...

Breyanzi is the first CAR-T cell therapy without an orphan drug status ‒ nevertheless, a considerable additional benefit was granted by the German HTA body...

Although an RCT was submitted for Abecma, no additional benefit was granted by the German HTA body...

Skysona was never launched in Germany as the HTD closed operations in Europe, partly because failing to convince European payers to adequately reimburse Zynteglo...

German HTA body stopped routine practice data collection, as the number of available patients for treatment with Tecartus is too low to generate meaningful results...